Cargando…
Identifying Biomarkers in Lymph Node Metastases of Esophageal Adenocarcinoma for Tumor-Targeted Imaging
INTRODUCTION: Tumor-targeted imaging is a promising technique for the detection of lymph node metastases (LNM) and primary tumors. It remains unclear which biomarker is the most suitable target to distinguish malignant from healthy tissue in esophageal adenocarcinoma (EAC). OBJECTIVE: We performed a...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113228/ https://www.ncbi.nlm.nih.gov/pubmed/32048177 http://dx.doi.org/10.1007/s40291-020-00448-9 |
_version_ | 1783513626223575040 |
---|---|
author | de Gouw, D. J. J. M. Rijpkema, M. de Bitter, T. J. J. Baart, V. M. Sier, C. F. M. Hernot, S. van Dam, G. M. Nagtegaal, I. D. Klarenbeek, B. R. Rosman, C. van der Post, R. S. |
author_facet | de Gouw, D. J. J. M. Rijpkema, M. de Bitter, T. J. J. Baart, V. M. Sier, C. F. M. Hernot, S. van Dam, G. M. Nagtegaal, I. D. Klarenbeek, B. R. Rosman, C. van der Post, R. S. |
author_sort | de Gouw, D. J. J. M. |
collection | PubMed |
description | INTRODUCTION: Tumor-targeted imaging is a promising technique for the detection of lymph node metastases (LNM) and primary tumors. It remains unclear which biomarker is the most suitable target to distinguish malignant from healthy tissue in esophageal adenocarcinoma (EAC). OBJECTIVE: We performed an immunohistochemistry study to identify viable tumor markers for tumor-targeted imaging of EAC. METHODS: We used samples from 72 patients with EAC to determine the immunohistochemical expression of ten potential tumor biomarkers for EAC (carbonic anhydrase IX [CA-IX], carcinoembryonic antigen [CEA], hepatic growth factor receptor, epidermal growth factor receptor, epithelial membrane antigen [EMA], epithelial cell adhesion molecule [EpCAM], human epidermal growth factor receptor 2 [HER-2], urokinase plasminogen activator receptor, vascular endothelial growth factor-A [VEGF-A], and VEGF receptor 2). Immunohistochemistry was performed on tissue microarrays of LNM (n = 48), primary EACs (n = 62), fibrotic tissues (n = 11), nonmalignant lymph nodes (n = 24), and normal esophageal and gastric tissues (n = 40). Tumor marker staining was scored on intensity and percentage of positive cells. RESULTS: EMA and EpCAM showed strong expression in LNM (> 95%) and primary EACs (> 95%). Significant expression was also observed for LNM and EAC using VEGF-A (85 and 92%), CEA (68 and 54%), and CA-IX (4 and 34%). The other tumor biomarkers showed expression of 0–15% for LNM and primary EAC. Except for VEGF-A, nonmalignant lymph node staining was scored as slight or absent. CONCLUSIONS: High expression rates and correlation between LNM in EAC combined with low expression rates in healthy lymph nodes and esophagus tissues were observed for EpCAM and CEA, meaning these are promising targets for tumor-targeted imaging approaches for lymph nodes in patients with EAC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40291-020-00448-9) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7113228 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-71132282020-04-06 Identifying Biomarkers in Lymph Node Metastases of Esophageal Adenocarcinoma for Tumor-Targeted Imaging de Gouw, D. J. J. M. Rijpkema, M. de Bitter, T. J. J. Baart, V. M. Sier, C. F. M. Hernot, S. van Dam, G. M. Nagtegaal, I. D. Klarenbeek, B. R. Rosman, C. van der Post, R. S. Mol Diagn Ther Original Research Article INTRODUCTION: Tumor-targeted imaging is a promising technique for the detection of lymph node metastases (LNM) and primary tumors. It remains unclear which biomarker is the most suitable target to distinguish malignant from healthy tissue in esophageal adenocarcinoma (EAC). OBJECTIVE: We performed an immunohistochemistry study to identify viable tumor markers for tumor-targeted imaging of EAC. METHODS: We used samples from 72 patients with EAC to determine the immunohistochemical expression of ten potential tumor biomarkers for EAC (carbonic anhydrase IX [CA-IX], carcinoembryonic antigen [CEA], hepatic growth factor receptor, epidermal growth factor receptor, epithelial membrane antigen [EMA], epithelial cell adhesion molecule [EpCAM], human epidermal growth factor receptor 2 [HER-2], urokinase plasminogen activator receptor, vascular endothelial growth factor-A [VEGF-A], and VEGF receptor 2). Immunohistochemistry was performed on tissue microarrays of LNM (n = 48), primary EACs (n = 62), fibrotic tissues (n = 11), nonmalignant lymph nodes (n = 24), and normal esophageal and gastric tissues (n = 40). Tumor marker staining was scored on intensity and percentage of positive cells. RESULTS: EMA and EpCAM showed strong expression in LNM (> 95%) and primary EACs (> 95%). Significant expression was also observed for LNM and EAC using VEGF-A (85 and 92%), CEA (68 and 54%), and CA-IX (4 and 34%). The other tumor biomarkers showed expression of 0–15% for LNM and primary EAC. Except for VEGF-A, nonmalignant lymph node staining was scored as slight or absent. CONCLUSIONS: High expression rates and correlation between LNM in EAC combined with low expression rates in healthy lymph nodes and esophagus tissues were observed for EpCAM and CEA, meaning these are promising targets for tumor-targeted imaging approaches for lymph nodes in patients with EAC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40291-020-00448-9) contains supplementary material, which is available to authorized users. Springer International Publishing 2020-02-11 2020 /pmc/articles/PMC7113228/ /pubmed/32048177 http://dx.doi.org/10.1007/s40291-020-00448-9 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Original Research Article de Gouw, D. J. J. M. Rijpkema, M. de Bitter, T. J. J. Baart, V. M. Sier, C. F. M. Hernot, S. van Dam, G. M. Nagtegaal, I. D. Klarenbeek, B. R. Rosman, C. van der Post, R. S. Identifying Biomarkers in Lymph Node Metastases of Esophageal Adenocarcinoma for Tumor-Targeted Imaging |
title | Identifying Biomarkers in Lymph Node Metastases of Esophageal Adenocarcinoma for Tumor-Targeted Imaging |
title_full | Identifying Biomarkers in Lymph Node Metastases of Esophageal Adenocarcinoma for Tumor-Targeted Imaging |
title_fullStr | Identifying Biomarkers in Lymph Node Metastases of Esophageal Adenocarcinoma for Tumor-Targeted Imaging |
title_full_unstemmed | Identifying Biomarkers in Lymph Node Metastases of Esophageal Adenocarcinoma for Tumor-Targeted Imaging |
title_short | Identifying Biomarkers in Lymph Node Metastases of Esophageal Adenocarcinoma for Tumor-Targeted Imaging |
title_sort | identifying biomarkers in lymph node metastases of esophageal adenocarcinoma for tumor-targeted imaging |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113228/ https://www.ncbi.nlm.nih.gov/pubmed/32048177 http://dx.doi.org/10.1007/s40291-020-00448-9 |
work_keys_str_mv | AT degouwdjjm identifyingbiomarkersinlymphnodemetastasesofesophagealadenocarcinomafortumortargetedimaging AT rijpkemam identifyingbiomarkersinlymphnodemetastasesofesophagealadenocarcinomafortumortargetedimaging AT debittertjj identifyingbiomarkersinlymphnodemetastasesofesophagealadenocarcinomafortumortargetedimaging AT baartvm identifyingbiomarkersinlymphnodemetastasesofesophagealadenocarcinomafortumortargetedimaging AT siercfm identifyingbiomarkersinlymphnodemetastasesofesophagealadenocarcinomafortumortargetedimaging AT hernots identifyingbiomarkersinlymphnodemetastasesofesophagealadenocarcinomafortumortargetedimaging AT vandamgm identifyingbiomarkersinlymphnodemetastasesofesophagealadenocarcinomafortumortargetedimaging AT nagtegaalid identifyingbiomarkersinlymphnodemetastasesofesophagealadenocarcinomafortumortargetedimaging AT klarenbeekbr identifyingbiomarkersinlymphnodemetastasesofesophagealadenocarcinomafortumortargetedimaging AT rosmanc identifyingbiomarkersinlymphnodemetastasesofesophagealadenocarcinomafortumortargetedimaging AT vanderpostrs identifyingbiomarkersinlymphnodemetastasesofesophagealadenocarcinomafortumortargetedimaging |